

## CJS Q1 2019 Updates Marketing Sheet

New	Upgrade	Lowering Estimates	Lowering Price Target	Dropping Coverage	Beat (Consensus)	Miss (Consensus)
VRRM ALG OEC UIS	RAVN	LCII PATK ASIX PRIM NOMD CALM RRD PRSC USCR	ASIX	BID SPA	CLH HELA	LCII PATK NP MATW HAE (FY20)

Focus Ideas (Market Cap, Px Tgt)		
VRRM	\$1,786	\$14
KAR	\$6,819	\$62
LGND	\$2,525	\$230
AAWW	\$1,301	\$93
LXFR	\$659	\$30
NOMD	\$4,032	\$25

Pullback Creates Opportunity	Show Me
ATRO	SPB
OEC	IVC
SKY	NNBR
ACA	OMN
	NCS
	PDFS

**Non-Deal Roadshows**

Please see the following page for the full NDR calendar.

Management Change	Strategic Alts.
ROCK	HELE
UFI	PRSC ?
LBY	CISN ?
NNBR	KN ?

Plant Tours		
SPB	5/14	STL
ROG	5/21	ARI
VRRM	5/21	ARI
CVCO	5/22	ARI
SKY	5/22	ARI

NDRs Sorted By City

<b>Ticker</b>	<b>Company</b>	<b>Date</b>	<b>City</b>
Updates to Coverage		4/2	
<b>ROG</b>	<b>Rogers Corporation</b>	5/21	<b>HQ Visit- AZ</b>
<b>VRRM</b>	<b>Verra Mobility</b>	5/21	<b>HQ Visit- AZ</b>
<b>CVCO</b>	<b>Cavco Industries, Inc.</b>	5/22	<b>HQ Visit- AZ</b>
<b>SKY</b>	<b>Skyline Champion Corp.</b>	5/22	<b>Plant Tour- AZ</b>
<i>CJS Quarterly Marketing</i>		4/16	<b>BAL</b>
<b>USPH</b>	<b>U.S. Physical Therapy, Inc.</b>	4/3	<b>BOS</b>
<i>CJS Quarterly Marketing</i>		4/9-10	<b>BOS</b>
<b>JW.A</b>	<b>John Wiley &amp; Sons, Inc.</b>	4/9	<b>BOS</b>
<b>CALM</b>	<b>Cal-Maine Foods, Inc.</b>	4/10	<b>BOS</b>
<b>ALG</b>	<b>Alamo Group</b>	5/14	<b>BOS</b>
<b>UFI</b>	<b>Unifi, Inc.</b>	5/16	<b>BOS</b>
<b>LXFR</b>	<b>Luxfer Holdings</b>	4/4	<b>CHI</b>
<b>SP</b>	<b>SP Plus Corporation</b>	4/8	<b>CHI</b>
<i>CJS Quarterly Marketing</i>		4/9	<b>CHI</b>
<b>FSS</b>	<b>Federal Signal Corp.</b>	4/9	<b>CHI</b>
<b>IVC</b>	<b>Invacare Corporation</b>	4/11	<b>CHI</b>
<b>VRRM</b>	<b>Verra Mobility</b>	5/8	<b>CHI</b>
<b>PRIM</b>	<b>Primoris Services Corporation</b>	5/14	<b>CHI</b>
<b>HAE</b>	<b>Haemonetics Corp.</b>	5/16	<b>CHI</b>
<b>MMS</b>	<b>MAXIMUS, Inc.</b>	5/22	<b>CHI</b>
<i>CJS Quarterly Marketing</i>		4/10-12	<b>DAL</b>
<b>IVC</b>	<b>Invacare Corporation</b>	4/10	<b>DAL</b>
<b>NX</b>	<b>Quanex Building Products</b>	4/11	<b>DAL</b>
<b>IVC</b>	<b>Invacare Corporation</b>	4/24	<b>DAL</b>
<b>HAE</b>	<b>Haemonetics Corp.</b>	5/15	<b>DEN</b>
<b>MMS</b>	<b>MAXIMUS, Inc.</b>	5/23	<b>DEN</b>
<i>CJS Quarterly Marketing</i>		4/10-12	<b>HOU</b>
<b>NX</b>	<b>Quanex Building Products</b>	4/10	<b>HOU</b>
<b>LXFR</b>	<b>Luxfer Holdings</b>	4/5	<b>MKE</b>
<i>CJS Quarterly Marketing</i>		4/3-4	<b>NYC</b>
<b>USPH</b>	<b>U.S. Physical Therapy, Inc.</b>	4/4	<b>NYC</b>
<b>KRNT</b>	<b>Kornit Digital Ltd.</b>	4/5	<b>NYC</b>
<b>CISN</b>	<b>Cision Ltd.</b>	4/8	<b>NYC</b>
<b>CALM</b>	<b>Cal-Maine Foods, Inc.</b>	4/9	<b>NYC</b>
<b>UFI</b>	<b>Unifi, Inc.</b>	5/15	<b>NYC</b>
<b>CVCO</b>	<b>Cavco Industries, Inc.</b>	5/30	<b>NYC</b>
<i>CJS Quarterly Marketing</i>		4/15	<b>PA/DE</b>
<b>SPB</b>	<b>Spectrum Brands Holdings</b>	5/14	<b>Plant Tour- STL</b>

## **IMPORTANT RESEARCH DISCLOSURES**

### **ANALYST CERTIFICATION**

As to each company covered in this compendium report, the respective research analyst certifies that the views expressed in this research report accurately reflect their personal views about the subject security and issuer. Furthermore, no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

### **Valuation Methodology**

For specific valuation methodologies please refer to the most recently published report for companies mentioned in this compendium report.

### **Risks**

For specific risks please refer to the most recently published report and/or SEC filings for companies mentioned in this compendium report.

### **STOCK RATING DEFINITIONS**

CJS Securities, Inc. Equity Research rating system

*Market Outperform (MO):* a stock that should perform at least 15% better than the Russell 2000 index over the next 6-18 months

*Market Perform (MP):* a stock that should perform in line with or slightly better than the Russell 2000 index

*Market Under-Perform (MU):* a stock expected to under-perform the Russell 2000 index

We may also have some stocks on a Monitor List, where we are indicating to clients not to expect a similar level of research coverage as companies on our active coverage list. Hence, we do not have investment opinions or price targets, nor do we intend to publish estimates, on Monitor list names.

### **RATINGS DISTRIBUTION AND BANKING RELATIONSHIPS (AS OF 4/1/19)**

CJS Securities provided active research on 106 companies, of which 87 (82%) are rated MO (buy) and 19 (18%) are rated MP (hold) and 0 (0%) are rated MU(sell). In addition to our active research there are 4 companies on our Monitor List as of 4/1/19 (no rating, estimates or price target).

The company has received investment banking fees from 6 companies (~6% of the companies under active coverage) and non-investment banking commissions from 15 companies (~15% of the companies under active coverage) in the past 12 months.

### **COMPANY SPECIFIC DISCLOSURES:**

CJS intends to seek compensation for investment banking and/or non-investment banking services from the subject company in the next three months and therefore may have a conflict of interest that may affect the objectivity of this report.

### **GENERAL DISCLAIMERS**

The information and statistics in this report have been obtained from sources we believe are reliable but we do not warrant their accuracy or completeness. Prices and opinions concerning the composition of market sectors included in this report reflect the judgments as of this date and are subject to change without notice. This material is for your information only and does not constitute an offer to buy or sell, or the solicitation of any offer to buy or sell any securities. CJS Securities Inc., its affiliates, directors, officers, stockholders, employees (or members of their families), and accounts with respect to which the forgoing have investment discretion, may have long or short positions in, and may, as principal or agent, buy or sell the securities mentioned herein. This report at issue was not prepared in light of the investment objectives of any particular client of the firm and the firm makes no representation of any kind that the recommendation set forth herein is suitable for any particular investor. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. The price, value of and income from any of the securities mentioned in this report can fall as well as rise. The value of securities is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities. This publication and any recommendation contained herein speak only as of the date hereof and are subject to change without notice. CJS Securities, Inc. accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to CJS Securities, Inc. This report is not to be relied upon in substitution for the exercise of independent judgment. CJS Securities and its employees shall have no obligation to update or amend any information or opinion contained herein, and the frequency of subsequent publications, if any, remain in the discretion of the author and the Firm.

**Reprints and/or redistribution of CJS Securities, Inc. research reports are strictly prohibited without prior permission.**

Member FINRA and SIPC

Additional information is available upon request. Copyright 2019, CJS Securities, Inc. All rights reserved.